Conference Coverage
Conference Coverage
Whole breast radiation for breast cancer shown to be safe and effective
Whole breast radiation can cut treatment time from 6 weeks down to 3 weeks.
Conference Coverage
Newer agents for nosocomial pneumonia: The right drug for the right bug
“The right drug at the right time with the right dose for the right bug for the right duration.”
Conference Coverage
‘Modest’ benefit for lecanemab in Alzheimer’s disease, but adverse events are common
The Food and Drug Administration is expected to make a decision about possible approval of the drug in January 2023.
Conference Coverage
NSAIDs for knee osteoarthritis may worsen pain over time
Researchers find no long-term benefit and worse inflammation and cartilage quality over 4 years.
Latest News
Consider radiologic imaging for high-risk cutaneous SCC, expert advises
Surgery may be the mainstay of treatment for resectable SCC, but the emerging role of neoadjuvant therapeutics is changing the way oncologists...
Conference Coverage
Immunotherapy may be path forward in HPV oropharyngeal cancer
Immunotherapy benefits locally advanced HPV-positive oropharyngeal cancer in phase 2 study.
Conference Coverage
Latinx and melanoma: Barriers and opportunities
A qualitative study in California reveals challenges and attitudes that could be addressed with new melanoma outreach and prevention strategies....
Conference Coverage
Future HIV PrEP innovations aim to address adherence, women’s health, and combination treatments
Only about 20% of people who could benefit from PrEP use the preventative medication.
Conference Coverage
People living with HIV are a model population for vaccination
The PLWH community can still offer valuable insights into effective ways to reach out to people.
Conference Coverage
PrEP education during STI testing could boost HIV protection
It comes down to numbers. More people seek screening for STIs compared with those who actively seek PrEP for HIV prevention.
Conference Coverage
Stage 3 melanoma attacked with immunotherapy and a virus-like particle
Phase 2 trial achieves some success, and responders had infiltrate of plasmacytoid dendritic cells.